Isoprenaline Hydrochloride Macure

Isoprenaline Hydrochloride, the active ingredient in Isoprenaline Hydrochloride Macure, is a beta‑adrenergic agonist presented as a sterile injectable solution for intravenous use. It is employed to increase heart rate in bradycardia, improve conduction in heart block, and relax airway smooth muscle in bronchospasm. GNH USA supplies Isoprenaline Hydrochloride Macure as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isoprenaline Hydrochloride acts on the cardiovascular and respiratory systems to counteract slow heart rhythms and bronchoconstriction. - Bradycardia: raises heart rate to restore adequate cardiac output. - Heart block: enhances atrioventricular conduction, reducing the degree of block. - Bronchospasm (asthma): relaxes bronchial smooth muscle, improving airflow during acute attacks.

Isoprenaline Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Palpitations - Tachycardia - Headache - Tremor - Nausea - Flushing

Serious or Rare Side Effects: - Life‑threatening arrhythmias - Myocardial ischemia - Severe hypotension - Pulmonary edema - Anaphylactic reaction

Careful monitoring and patient assessment are essential when using Isoprenaline Hydrochloride. - Cardiac monitoring: observe heart rate and rhythm continuously during infusion. - Dose titration: start with the lowest effective dose and adjust based on clinical response. - Contraindications: avoid in patients with uncontrolled tachyarrhythmias. - Caution in ischemic heart disease: increased myocardial oxygen demand may precipitate ischemia. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Isoprenaline Hydrochloride can interact with several drug classes, requiring attention to avoid reduced efficacy or heightened toxicity.

Major Interactions (Avoid): - Beta‑blockers: block beta‑adrenergic stimulation, diminishing therapeutic effect. - MAO inhibitors: may amplify cardiovascular stimulation, increasing risk of hypertension. - Calcium channel blockers: can potentiate hypotensive episodes.

Moderate Interactions (Monitor Closely): - Digitalis glycosides: may increase the risk of arrhythmias. - Sympathomimetic agents: additive tachycardia and hypertension may occur.